Skip to content

Vera Therapeutics VERA Free cash flow yield

Free cash flow yield at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
3.3%+2.2pp
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
-25.1%-6.6pp
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-9.9%-4.8pp
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-15.2%-4.4pp
Immunome logo
ImmunomeIMNM
-8.3%-3.4pp
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
-21.1%-5.3pp

Other financials

Income statement

See full
Operating income-$125.1M-119%
Net income-$121.0M-134%
EPS (diluted)-$1.69-109%

Balance sheet

See full
Cash & equivalents$114.4M+108%
Total debt$75.0M+37.8%
Total equity$499.7M-6.6%
Total assets$621.7M+1.9%

Cash flow

See full
Operating cash flow-$106.5M-95.8%
CapEx$23.0K-87.7%
Free cash flow-$106.5M-95.1%

Valuation

See full
Market cap$2.74B+87.5%
Enterprise value$2.7B+85.0%

Returns & leverage

See full
Return on equity-71.3%+296pp
Debt / equity0.2×0.0×
Current ratio13.6×-14.0×

Where this comes from

Calculated from Vera Therapeutics’s reported figures.

Based on trailing twelve months.

The official record: Vera Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vera Therapeutics's free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vera Therapeutics's free cash flow yield?
Vera Therapeutics (VERA) reported free cash flow yield of -10.2% in Q1 2026.
How has Vera Therapeutics's free cash flow yield changed year-over-year?
Vera Therapeutics's free cash flow yield decreased by 0.1% year-over-year, from -10.2% to -10.2%.
What is the long-term trend for Vera Therapeutics's free cash flow yield?
Over 4 years (2021 to 2025), Vera Therapeutics's free cash flow yield has grown at a 16.4% compound annual growth rate (CAGR), from -3.7% to -6.7%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.